JP2004531567A5 - - Google Patents

Download PDF

Info

Publication number
JP2004531567A5
JP2004531567A5 JP2002592909A JP2002592909A JP2004531567A5 JP 2004531567 A5 JP2004531567 A5 JP 2004531567A5 JP 2002592909 A JP2002592909 A JP 2002592909A JP 2002592909 A JP2002592909 A JP 2002592909A JP 2004531567 A5 JP2004531567 A5 JP 2004531567A5
Authority
JP
Japan
Prior art keywords
stabilizers
wetting agents
liquid solvents
dispersions
suspensions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002592909A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004531567A (ja
JP4746258B2 (ja
Filing date
Publication date
Priority claimed from DE10125882A external-priority patent/DE10125882B4/de
Application filed filed Critical
Publication of JP2004531567A publication Critical patent/JP2004531567A/ja
Publication of JP2004531567A5 publication Critical patent/JP2004531567A5/ja
Application granted granted Critical
Publication of JP4746258B2 publication Critical patent/JP4746258B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002592909A 2001-05-28 2002-05-27 薬剤 Expired - Fee Related JP4746258B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10125882A DE10125882B4 (de) 2001-05-28 2001-05-28 Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus
DE10125882.8 2001-05-28
PCT/EP2002/005811 WO2002096398A2 (de) 2001-05-28 2002-05-27 Arzneimittel enthaltend einen effektor des glutathionmetabolismus zussammen mit $g(a)-liponsäure im rahmen der behandlung des diabetes mellitus

Publications (3)

Publication Number Publication Date
JP2004531567A JP2004531567A (ja) 2004-10-14
JP2004531567A5 true JP2004531567A5 (https=) 2009-08-20
JP4746258B2 JP4746258B2 (ja) 2011-08-10

Family

ID=7686361

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002592909A Expired - Fee Related JP4746258B2 (ja) 2001-05-28 2002-05-27 薬剤

Country Status (9)

Country Link
US (1) US7429614B2 (https=)
EP (2) EP1529529B1 (https=)
JP (1) JP4746258B2 (https=)
AT (2) ATE303145T1 (https=)
AU (1) AU2002344178A1 (https=)
DE (3) DE10125882B4 (https=)
ES (2) ES2247377T3 (https=)
PT (1) PT1529529E (https=)
WO (1) WO2002096398A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303229B4 (de) * 2003-01-28 2007-07-26 Keyneurotek Ag Ambroxol und Inhibitoren des Angiotensin Converting-Enzyms (ACE) umfassende Arzneimittel Arzneimittel-Zubereitung und ihre Verwendung zur Behandlung von neurodegenerativen Erkrankungen
DE10360954B3 (de) * 2003-12-23 2005-08-18 Esparma Gmbh Verwendung von Silibinin, dessen Salzen und/oder dessen Prodrugs zusammen mit α-Liponsäure zur Behandlung chronisch obstruktiver Lungenerkrankungen
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
EP1817058B1 (en) * 2004-11-24 2015-09-02 Hill's Pet Nutrition, Inc. Composition for use in improving liver clearance of xenobiotic substances in an animal
US20100099751A1 (en) * 2008-10-21 2010-04-22 Al-Mulla Fahd Method of treating diabetes-related vascular complications
JP2012510511A (ja) * 2008-12-01 2012-05-10 インヴアスク セラピューテイックス インコーポレイテッド レニン−アンジオテンシン−アルドステロン系阻害剤及びリポ酸化合物を含有する組成物、並びに、レニン−アンジオテンシン−アルドステロン系に関連した疾患の治療のためのそれらの使用
CN113244265B (zh) * 2021-03-23 2023-07-14 武汉广行科学研究有限公司 配体修饰的硫化锌纳米粒子、制备方法及其在治疗中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT95826B (pt) * 1989-11-09 1997-11-28 Asta Medica Ag Processo para a preparacao de composicoes farmaceuticas contendo como ingrediente activo acido r-alfa-liponico ou acido s-alfa-liponico
DE4218572A1 (de) * 1992-06-05 1993-12-09 Asta Medica Ag Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
DE4343593C2 (de) * 1993-12-21 1998-05-20 Asta Medica Ag Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz
DE4420102A1 (de) * 1994-06-09 1995-12-14 Asta Medica Ag Arzneimittelkombinationen aus alpha-Liponsäure und herz-kreislaufaktiven Substanzen
GB9715444D0 (en) * 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
EP1047450B1 (en) * 1997-12-23 2002-10-02 Warner-Lambert Company Ace inhibitor-mmp inhibitor combinations
DE19806354B4 (de) * 1998-02-10 2004-09-16 Bdd Group Holding Ag Verwendung von α-Liponsäure oder deren physiologisch verträgliche Salze zur Behandlung von LDL-Hypercholesterinämie
JP2000309543A (ja) * 1999-04-28 2000-11-07 Ajinomoto Co Inc 抗糖尿病剤
DE10125883A1 (de) * 2001-05-28 2002-12-12 Serumwerk Bernburg Ag Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie

Similar Documents

Publication Publication Date Title
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2001062737A3 (en) Amino pyrazole derivatives useful for the treatment of obesity and other disorders
JP2005526147A5 (https=)
WO2003087094A3 (en) Pyrrolidinium derivatives as antagonists of m3 muscarinic receptors
WO2006035417A3 (en) Dihydropyrimidine microcapsule - formulations
IL164222A0 (en) Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
DE602004024375D1 (de) Carboxamidderivate
CA2521509A1 (en) Fast dissolving orally consumable films containing pharmaceutically active agents
JP2005524658A5 (https=)
DE602005025083D1 (https=)
IL203923A (en) Benzamide compounds, pharmaceutical compositions comprising them, use thereof in the preparation of medicaments and as medicaments and processes for the preparation of such compounds
CA2462606A1 (en) Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer
WO2006073419A3 (en) Lipoprotein nanoplatforms
YU38802A (sh) Nova kompozicija i njena upotreba
JP2006517944A5 (https=)
DE60105448D1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
JP2007537301A5 (https=)
WO2006116148A3 (en) (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse
IL175220A (en) 3,5-substituted estrone derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments for inhibiting 17beta-hydroxysteroid dehydrogenase type i enzyme
WO2003053945A3 (en) Urea derivatives and their use as vanilloid receptor antagonists
TW200624431A (en) Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
JP2004531567A5 (https=)
WO2004043362A3 (en) Acyl guanidine compounds and use thereof
WO2002072571A3 (en) Pyridinyl pyrazoles useful for the treatment of copd
IL181216A0 (en) 3, 5-seco-4-norcholestane derivatives and pharmaceutical compositions containing the same